Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Syros Pharmaceuticals
A subset of participants have MDS characterized by an overexpression of the RARA gene. A blood test will be used to identify participants with RARA-positive MDS. Assessment of the RARA biomarker for study eligibility will be done by collection of blood samples from potential study participants at the pre-screening visit and testing at a central laboratory. Participants who meet eligibility requirements will be randomized 2:1 to receive either Tamibarotene plus azacitidine or placebo plus azacitidine.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must be RARA-positive based on the investigational assay.
Participants must be newly diagnosed with HR-MDS as follows:
* Diagnosis of MDS according to the World Health Organization (WHO) classification and classified by the Revised International Prognostic Scoring System (IPSS R) risk category as very high, high, or intermediate risk.
Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2.
You may not be if
Participants are suitable for and agree to undergo allogeneic hematopoietic stem cell transplant (HSCT) at the time of screening.
* Participants who need treatment prior to stem cell transplant can receive treatment on this study and stop the study treatment when they are ready to proceed to transplant.
Participants who received prior treatment for MDS with any hypomethylating agent, lenalidomide, chemotherapy or allogeneic HSCT.
